Post

New research · Ophthalmology
Therapeutic advances in ophthalmology · 1w
Randomized trialTherapeutic advances in ophthalmology · 2026

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Diana V Do, Charles C Wykoff, Sobha Sivaprasad … Alyson J Berliner
Read paper
OphthalmologyRandomized trial

Most people with diabetic macular edema kept aflibercept 8 mg dosing every 12 weeks or longer

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Diana V Do … Alyson J Berliner
Therapeutic advances in ophthalmology · 2026
Purpose

The objective of the PHOTON study was to find out whether a higher dose of aflibercept (8 mg), injected every 12 or 16 weeks after 3 initial monthly injections, was as effective as aflibercept 2 mg injected every 8 weeks after 5 initial monthly injections.

Methods

During the 96-week study, study participants could receive aflibercept 8-mg injections more or less frequently than the schedule they were assigned depending on whether diabetic macular edema was worsening or improving.

More than 80%
Results
More than 80%
went at least 12 weeks between eye injections without needing more frequent shots
More results

This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology .

People who received aflibercept 8 mg received fewer and less frequent eye injections than those who received aflibercept 2 mg.

More results

After 96 weeks, study participants who received aflibercept 8 mg every 12 weeks or longer following 3 initial monthly injections maintained similar improvements in vision, with fewer injections, compared to those treated with aflibercept 2 mg every 8 weeks following 5 initial monthly injections.

“
Conclusion

The authors developed this plain language summary to help people living with diabetic macular edema, care partners, patient advocates, healthcare professionals, insurance providers, and policy makers to better understand the results of the PHOTON study.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving